Abstract
In nasopharyngeal carcinoma (NPC), Fas-ligand (Fas-L)-mediated apoptosis might contribute to the immune privilege of tumors. In some cancers, dysregulation of Fas-L protein in tumors might lead to disease progression. The purpose of this study was to evaluate the correlations between Fas-L expression and the clinical outcomes in patients with NPC. We recruited 78 patients with primary NPC, classified clinical stages according to the 1997 American Joint Committee on Cancer staging system, and assessed Fas-L with immunohistochemical methods. Forty-one (53%) of 78 patients were Fas-L-positive. The prevalence was 0%, 57%, 58%, and 82% from stages I to IV, respectively (p <.001). Fas-L expression was associated with the N classification (p=.05) but not the T classification. Patients with positive Fas-L expression had a lower rate of disease-free survival and overall survival (p=.01 for all log-rank tests). Patients with NPC with Fas-L-positive tumors had higher clinical stages and lymph node metastasis at diagnosis and poorer disease-free survival and overall survival; therefore, Fas-L expression may be a potential biomarker of prognosis.
References
Sep 1, 1979·Cancer·K ShanmugaratnamC Y Tye
Apr 1, 1988·European Journal of Immunology·C SieplA Fontana
Nov 1, 1989·Head & Neck·M M HsuL T Lui
Jan 15, 1980·International Journal of Cancer. Journal International Du Cancer·U GaliliI Singh Bal
Jun 1, 1981·Cellular Immunology·P E BakerA Munck
Aug 1, 1993·Japanese Journal of Cancer Research : Gann·Y S ZongZ F Yu
Feb 1, 1996·Cellular Immunology·H CuiS T Ju
Mar 1, 1996·Immunity·L Van ParijsA K Abbas
Nov 22, 1996·Science·M HahneJ Tschopp
Dec 1, 1996·Nature Medicine·S StrandP R Galle
Feb 12, 1998·Proceedings of the National Academy of Sciences of the United States of America·H AraiG J Nabel
Mar 31, 1999·British Journal of Cancer·B MannC Hanski
Jan 25, 2000·Oral Oncology·S T TsaiB C Yang
Mar 4, 2000·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·J T ChangJ H Hong
Mar 29, 2000·British Journal of Cancer·Y ItoN Matsuura
Feb 7, 2001·International Journal of Cancer. Journal International Du Cancer·M MottoleseF M Venanzi
Apr 26, 2000·British Journal of Cancer·S MunakataK Aozasa
Apr 27, 2000·Cancer Immunology, Immunotherapy : CII·N Nagarkatti
May 19, 2000·British Journal of Cancer·M Volm, R Koomägi
Dec 21, 2000·International Journal of Radiation Oncology, Biology, Physics·S H ChengA T Huang
Mar 7, 2001·Nature Medicine·J O'ConnellF Shanahan
Aug 3, 2001·International Journal of Radiation Oncology, Biology, Physics·J MaH Q Min
Dec 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R L HongL T Lui
Feb 22, 2002·Cancer·Jenn-Ren HsiaoSen-Tien Tsai
Citations
Jul 27, 2010·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Mei-Chi HsuYao Chang
Nov 14, 2008·Blood·Jihène KlibiPierre Busson
Dec 13, 2006·BMC Cancer·Cécile Keryer-BibensPierre Busson
Jan 25, 2011·Journal of Experimental & Clinical Cancer Research : CR·Caigan Du, Yuzhuo Wang
Dec 17, 2014·Journal of the National Cancer Institute·Dhafer MrizakNadira Delhem
Jan 18, 2012·Seminars in Cancer Biology·Claire GourzonesPierre Busson
Feb 23, 2007·International Journal of Cancer. Journal International Du Cancer·Takeshi OginoSoldano Ferrone
Sep 16, 2010·Molecular Carcinogenesis·Yun CaoJian-Yong Shao
Oct 12, 2013·Cancer·Xu LiuJun Ma
Sep 6, 2017·Scientific Reports·Tseng-Cheng ChenYih-Leong Chang
Aug 19, 2010·Molecular Cancer Therapeutics·Ming-Ying LanChi-Ying F Huang
Apr 4, 2021·Cancers·Foteinos-Ioannis DimitrakopoulosAngelos Koutras